| ²é¿´: 1766 | »Ø¸´: 5 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
¡¾ÇóÖú¡¿ÇóÖú¹ØÓÚÒÁÅËÁ¢ÍªµÄ˵Ã÷Êé
|
|||
| ¹úÍâ¹ØÓÚÒÁÅËÁ¢Íª±¾ÉíµÄÏà¹ØÎÄÏ×±¨µÀ£¬ËµÃ÷Ê鼰רÀû¾ù¿É¡£ÏÈлл´ó¼Ò£¡ |
» ²ÂÄãϲ»¶
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
105500ҩѧµ÷¼Á£¬Ò»Ö¾Ô¸¶¥9£¬Ö÷³ÖÊ¡¼¶´ó´´£¬ÊµÑéÐÍSCI¶þ×÷£¬ËÄÁù¼¶Òѹý£¬Ë«¹ú½±
ÒѾÓÐ6È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ258È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ20È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ҩѧר˶µ÷¼Á
ÒѾÓÐ0È˻ظ´
publcifµÄʹÓÃ
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
»á¼Æ×¨Ë¶Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
ÒѾÓÐ12È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
ÎïÀíѧ µ÷¼Á
+1/85
Õã½Å©ÁÖ´óѧÕÐÊÕµ÷¼Á
+1/80
ÎÂÖÝ´óѧÂÀ¾§¾§¿ÎÌâ×é2026ÄêÕÐÉú
+1/80
ÏæÌ¶´óѧ»¯¹¤Ñ§Ôº¹ú¼Ò¼¶È˲ÅÍŶÓ2026Ä격ʿÑо¿ÉúÕÐÉú
+1/64
0854µç×ÓÐÅÏ¢µ÷¼Á£¬ÃöÄÏʦ´ó¹âµçоƬÑз¢ÊµÑéÊÒ
+1/42
»ªÄÏʦ·¶´óѧ£¨211£©²©Ê¿ÕÐÉú- µç×Ó¡¢×Ô¶¯»¯¡¢»úе¡¢ÉúÎïѧ¡¢ÎïÀíÏà¹Ø×¨Òµ
+2/38
»¶Ó½»Á÷×Éѯ
+1/37
2026ÄêÖØÇ칤ÉÌ´óѧ¹ÜÀí¿ÆÑ§Ó빤³ÌרҵѧÊõ˶ʿÕÐÉúµ÷¼Á£¬·ç¾°×ÜÔÚÁø°µ»¨Ã÷´¦
+1/35
ÏæÌ¶´óѧ¡°¹ý³ÌÇ¿»¯ÓëÂÌÉ«»¯¹¤¡±´´ÐÂÍŶӲ¹ÕÐ2026ÄêÇïÈëѧ²©Ê¿Éú
+1/35
»ªÄÏʦ·¶´óѧ£¨211£©ÉêÇëÉóºËÖÆ²©Ê¿ÕÐÉú- µç×Ó¡¢×Ô¶¯»¯¡¢»úе¡¢ÉúÎïѧ¡¢ÎïÀíÏà¹Ø×¨Òµ
+1/25
ÕÐÊÕµ÷¼ÁÉú ¹ú¼ÒÖØµãʵÑéÊÒ£¨¹ãÎ÷ijʦ·¶´óѧ¡¢BÇø£©
+1/17
Call for paper: [Fermentation ¨C IF 3.3]
+2/14
¿ÎÌâ×éÕÐÊÕ»·¾³¼°Ïà¹Ø×¨Òµµ÷¼Á˶ʿÑо¿Éú£¨»¶ÓÓÅÐãѧÉú¼ÓÈ룩
+1/6
ÄÏ·½¿Æ¼¼´óѧ»ù´¡ÃâÒßÓë΢ÉúÎïѧϵÕÐÆ¸¿ÆÑÐÖúÀí1-2Ãû£¬´ÓÊÂ΢ÉúÎïÓëÃâÒßѧ·½ÏòÑо¿
+1/5
˫һÁ÷Ìì½ò¹¤Òµ´óѧµçÐÅѧԺÀîºèÇ¿½ÌÊÚÕÐÊÕ2026ÄêÉêÇëÉóºËÖÆ²©Ê¿3Ãû
+1/4
ÖÐɽ´óѧº£¿ÆÔº¿ÎÌâ×éÕÐÊÕ˶ʿÑо¿Éú
+1/4
²©ºó¼´½«³öÕ¾£¬ÇóÎȶ¨µÄ½ÌÖ°
+1/3
339Çóµ÷¼Á
+1/1
Î÷°²½»Í¨´óѧÉúÃüѧԺÖÇÄÜ»¯ÕïÁÆ×°±¸Ñо¿ÖÐÐÄ2026Ä격ʿÉúÕÐÉú
+1/1
¡¾2026Äê´º¼¾²¹Â¼¡¿ÏÃÃÅ´óѧÌïÖÐȺԺʿ/Ò׿¥½ÌÊÚÄÉÃ×¹â×ÓѧÍŶÓÕÐÊÕ2026ÄêÈëѧ²©Ê¿Éú
+1/1
zsc
Ìú¸Ëľ³æ (СÓÐÃûÆø)
- DRDEPI: 1
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 6652.4
- Ìû×Ó: 230
- ÔÚÏß: 278.2Сʱ
- ³æºÅ: 309535
yangjing561(½ð±Ò+4): 2011-01-14 16:07:11
|
http://www.accessdata.fda.gov/sc ... =Search.DrugDetails FDAÏà¹Ø×ÊÁÏ£¬ËµÃ÷Êé ÈýÏîÖØÒªÏà¹Ø×¨Àû£¬µÚÒ»ÏîרÀû£¬ÉêÇëºÅ£º90103721.4£¬ÉêÇëÈÕ£º1990.05.19 רÀûµ½ÆÚʱ¼ä£º2010Äê05ÔÂ19ÈÕ£¬Ãû³Æ£ºN-(·¼Ñõ»ùÍé»ù)ÔÓ·¼»ùßÉ़°Ò»ÔÓ·¼»ùßÉàº,ËüÃǵÄÖÆ±¸·½·¨ÒÔ¼°ËüÃÇ×÷ΪҩÎïµÄÓ¦ÓᣵڶþÏîרÀû£¬ÉêÇëºÅ£º 00130979.X£¬ÉêÇëÈÕ£º1990.05.19 £¬×¨Àûµ½ÆÚʱ¼ä£º2010Äê05ÔÂ19ÈÕ£¬Ãû³Æ£ºN£(·¼Ñõ»ùÍé»ù)ÔÓ·¼»ùßÉ़°Ò»ÔÓ·¼»ùßÉàº,×÷ΪҩÎïµÄÓ¦ÓᣵÚÈýÏîרÀû£¬ÉêÇëºÅ£º94194302.X ÉêÇëÈÕ£º1994.10.27£¬×¨Àûµ½ÆÚʱ¼ä£º2014Äê10ÔÂ27ÈÕ£¬Ãû³Æ£º·¼ÔÓ»·»ùßßà¤Àà¡¢ßÁ¿©ÍéÀ༰ßßàºÀ༰Æä×÷Ϊ¿¹¾«Éñ²¡Ò©ºÍֹʹҩµÄÓÃ;¡£ http://www.drugfuture.com/fda/nda022192_001.html Õâ¸öÒ²¿ÉÒÔ |
3Â¥2011-01-14 14:07:11
yangjing561(½ð±Ò+4): 2011-01-14 16:07:03
|
Reference 1: Corbett, R.; Bordeau, K.J.; Helsley, G.C.; Szewczak, M.R.; Wilmot, C.A.; Chiang, Y.; Hartman, H.B.; Conway, P.G.; Glamkowski, E.J.; Strupczewski, J.T.; 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of iloperidone (HP 873). J Med Chem 1995, 38, 7, 1119-31. Reference 2: Strupczewski, J.T.; Helsley, G.C.; Chiang, Y.; Bordeau, K.J. (Aventis Pharmaceuticals, Inc.); N-(Aryloxyalkyl)heteroarylpiperidines and-heteroarylpiperazines, a process for their preparation and their use as medicaments. EP 0402644; JP 1991063263 . Reference 3: Strupczewski, J.T.; Helsley, G.C.; Chiang, Y.; Bordeau, K.J.; Glamkowski, E.J. (Aventis Pharmaceuticals, Inc.); Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics. EP 0542136; EP 0612318; EP 0730452; EP 0957102; EP 0959075; EP 0959076; EP 0963984; JP 1995501055; JP 1997511215; US 5364866; US 5776963; WO 9309102; WO 9511680 . Reference 4: Mucke, H.A.M.; Castaner, J.; Iloperidone. Drugs Fut 2000, 25, 1, 29. Reference 5: Strupczewski, J.T.; Allen, R.C.; Gardner, B.A. (Aventis Pharmaceuticals, Inc.); 3-(4-Piperidyl)-1,2-benzisoxazoles. US 4355037 . |
2Â¥2011-01-14 13:56:17
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
| Õâ¸öÒ©ÊDz»ÊÇÓÐÖйúµÄ¾§ÐÍרÀûºÍÓÃ;רÀû°¡£¿ |
4Â¥2011-05-11 17:03:04
¡ï
lk590(½ð±Ò+1): лл²ÎÓë 2011-09-13 12:44:36
lk590(½ð±Ò+1): лл²ÎÓë 2011-09-13 12:44:36
|
ÓÃ;µÄרÀûºÜ¶à£¬»¹ÓÐһƪÊÇÌáµ½¾§Ð͵ÄרÀûwo 2004006886A2 |
5Â¥2011-05-12 10:31:02













»Ø¸´´ËÂ¥
